Advanced search
Publication Cover
Modern Rheumatology Volume 27, 2017 - Issue 2
Journal homepage
601
Views
27
CrossRef citations to date
0
Altmetric
Original Article

Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever

Orhan KucuksahinDivision of Rheumatology, Yildirim Beyazit University, Ankara, Turkey,
,
Mustafa Turgut YildizgorenDepartment of Physical Medicine and Rehabilitation, Mustafa Kemal University Medical School, Hatay, Turkey, Correspondence[email protected]
,
Ufuk IlgenDepartment of Internal Medicine, Ankara University Medical School, Ankara, Turkey, and
,
Askin AtesDepartment of Rheumatology, Ankara, Turkey
,
Gülay KinikliDepartment of Rheumatology, Ankara, Turkey
,
Murat TurgayDepartment of Rheumatology, Ankara, Turkey
&
Sukran ErtenDivision of Rheumatology, Yildirim Beyazit University, Ankara, Turkey,
show all
Pages 350-355 | Received 15 Jan 2016, Accepted 22 May 2016, Published online: 22 Jun 2016

References

  • Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol. 2013;45;117–30.
  • Ben-Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Isr Med Assoc J. 2014;16:271–73.
  • Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF – definition, causes and suggested solutions. Clin Exp Rheumatol. 2008;26:49–51.
  • Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29:77–86.
  • Gul A. Treatment of familial Mediterranean fever: colchicine and beyond. Isr Med Assoc J. 2014;16:281–4.
  • Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or-intolerant familial mediterranean fever: a randomized trial. Ann Int Med. 2012;157:533–41.
  • Meinzer U, Alexandra JF, Retornaz F. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41;265–71.
  • Ozen S, Bilginer Y, Aktay Ayaz Y, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38:516–18.
  • Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, et al. Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation 2015;38:27–31.
  • McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc) 2009;45:423–30.
  • Rigante D, Ansuini V, Berfoni B, Pugliese AL, Avallone L, Federico G, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int. 2006;27:97–100.
  • Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S, et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis. 2011;70:1511–12.
  • Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142:1591–7.
  • Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43:387–91.
  • Bagci S, Toy B, Tuzun A, Ates Y, Aslan M, Inal A, et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol. 2004; 23:333–7.
  • Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146:825–6.
  • Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676–8.
  • Anonymous. DRUGDEX Evaluations. Available from: http://www.thomsonhc.com [last accessed 22 Jul 2008].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.